MCC Publishes Its Groundbreaking, In-Depth Study of Risk-Based Monitoring Practices Currently Utilized in the Industry - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
MCC Publishes Its Groundbreaking, In-Depth Study of Risk-Based Monitoring Practices Currently Utilized in the Industry

Source: Company News Release

Today MCC released its groundbreaking, in-depth report on risk-based monitoring practices, “Taking the Risk-Based Monitoring Plunge: Who’s doing it, how they’re approaching it, and the metrics they’re using to manage it.” This survey represents another unique and valuable addition to an already rich and growing portfolio of metrics, performance-enhancing services, publications and tools offered to MCC members.

The new RBM Report released today gives current RBM users the ability to compare the RBM methods they currently employ to those utilized by a large sample of biopharmaceutical, CRO and academic research organizations. It gives new RBM users information that will allow them to accelerate and focus their implementation. The report includes over 40 figures, tables and graphs covering a wide range of topics including:

· Which types of organizations are undertaking RBM in which trial phases and regions

· The methods and approaches being used including, central data analytics and on-site monitoring strategies

· The typical and preferred metrics being used to trigger on-site monitoring visits

The report includes a detailed evaluation of RBM approaches compared to expectations set forth in the final FDA Guidance on RBM, and puts the MCC survey into context by comparing and contrasting its results with other recent industry surveys.

“This report helps both new and seasoned RBM users improve and focus their RBM efforts. This furthers our goal of helping companies within the industry understand, adopt and utilize metrics to drive performance quality and improvement,” stated MCC CEO David Zuckerman. “Today’s announcement is yet another example of our efforts to make MCC metrics more useful and relevant to the right users at the right time”.

The new MCC RBM Monitoring study is available for purchase through MCC.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Company News Release,
Click here